PCI Appropriateness Criteria Draw CriticismPCI Appropriateness Criteria Draw Criticism
A detailed critique of the national appropriate-use criteria for PCI--questioning the composition of the committee that wrote the criteria, some of the AUCs themselves, and the survey that compared the AUC with current clinical practice--has been published Heartwire (Source: Medscape Today Headlines)

FDA panel votes against wider use of Amgen drug
WASHINGTON (Reuters) - An advisory panel on Wednesday recommended that U.S. health regulators reject the use of Amgen Inc's drug Xgeva to delay the spread of prostate cancer to the bone, dimming the chance of a wider use for one of the company's key growth drivers. (Source: Reuters: Health)